Borderline ovarian tumors: evaluation of clinical, imaging, and morphological diagnostic methods
DOI:
https://doi.org/10.52692/1857-0011.2025.2-82.12Keywords:
borderline ovarian tumors, CA-125, diagnosis, ER expression, fertility preservation, histopathology, immunohistochemistry, imaging, PR expression, tumor markersAbstract
Borderline ovarian tumors (BOTs) represent a distinct subtype of epithelial ovarian neoplasms, with features intermediate between benign and malignant tumors. This retrospective-prospective study, conducted between 2010 and 2024, included 156 patients diagnosed with BOTs at the Institute of Oncology and “Nicolae Testemițanu” State University of Medicine and Pharmacy. The evaluation included clinical examination, imaging, serum tumor markers (CA-125,CA19-9, CEA), histopathological analysis, and immunohistochemical profiling (Ki-67, p53, ER, PR).Results revealed a predominance of serous forms (70.5%) and a high incidence of BOTs in women under 50 years of age. The CA-125 marker was elevated in 64.7% of cases and positively correlated with tumor stage. Immunohistochemical analysis showed high expression of ER, PR, p53, and Ki-67. The mean tumor size was 14.12 cm, and bilateral localization was observed in 41.7% of patients. The study supports the need for an integrated and personalized diagnostic algorithm to optimize oncological management and preserve fertility in selected patients.
References
Tropé CG, Kristensen GB, Abeler VM. Diagnosis and treatment of borderline ovarian tumors. Best Practice & Research Clinical Obstetrics & Gynaecology. 2012; 26(3): 325–336.
Kurman RJ, Shih IM. The origin and pathogenesis of epithelial ovarian cancer: a proposed unifying theory. American Journal of Surgical Pathology. 2016; 40(4): 403–423.
Shappell HW, Riopel MA, Smith Sehdev AE, Ronnett BM, Kurman RJ. Diagnostic criteria and behavior of ovarian borderline tumors. International Journal of Gynecological Pathology. 2002; 21(4): 407–416.
du Bois A, Ewald-Riegler N, de Gregorio N, Reuss A, Mahner S, Fotopoulou C, et al. Borderline tumors of the ovary: a systematic review. Geburtshilfe und Frauenheilkunde. 2013; 73(4): 321–330.
Morice P, Uzan C, Fauvet R, Duvillard P, Darai E. Borderline ovarian tumor: pathological diagnostic dilemma and risk factors of recurrence. Gynecologic Oncology. 2012; 125(3): 624–631.
Seidman JD, Kurman RJ, Ronnett BM, Shih IM. Pathology of borderline tumors of the ovary. Cancer. 2004; 100(10): 2191–2195.
McCluggage WG. Morphological subtypes of ovarian borderline tumors: their clinicopathological features and diagnostic challenges. Histopathology. 2010; 57(4): 423–443.
Silva EG, Deavers MT, Malpica A. Immunohistochemical markers in the differential diagnosis of ovarian tumors. Modern Pathology. 2020; 33(S1): 34–45.
American College of Obstetricians and Gynecologists (ACOG). Management of adnexal masses. Obstetrics & Gynecology. 2015; 126(3): e130–e143.
Trimble CL, Trimble EL, Kosary C, et al. Surgical management of borderline ovarian tumors. Clinical Obstetrics and Gynecology. 2002; 45(2): 407–414.
Uzan C, Kane A, Rey A, Gouy S, Duvillard P, Morice P. Fertility sparing management of borderline ovarian tumours: a French multicenter study. Human Reproduction. 2011; 26(12): 3127–3132.
Fauvet R, Boccara J, Dufournet C, Poncelet C, Daraï E. Fertility-sparing surgery for borderline ovarian tumors. Human Reproduction. 2005; 20(6): 1626–1630.
Downloads
Published
License
Copyright (c) 2026 Bulletin of the Academy of Sciences of Moldova. Medical Sciences
This work is licensed under a Creative Commons Attribution 4.0 International License.
